嚢胞性線維症治療のアジア太平洋市場2020-2058

◆英語タイトル:ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET FORECAST 2020-2028
◆商品コード:INK20MY109
◆発行会社(リサーチ会社):Inkwood Research
◆発行日:2020年3月
◆ページ数:104
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:アジア太平洋
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥137,500見積依頼/購入/質問フォーム
Multi LicenseUSD1,500 ⇒換算¥165,000見積依頼/購入/質問フォーム
Enterprisewide PriceUSD2,000 ⇒換算¥220,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Inkwood Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

KEY FINDINGSThe cystic fibrosis therapeutics market of Asia Pacific is estimated to record a CAGR of 9.58% during the projected period of 2020-2028.The rising research and development activities in terms of novel cystic fibrosis therapeutics are anticipated to create lucrative opportunities in the future.

MARKET INSIGHTS
In order to analyze the scope of the Asia Pacific cystic fibrosis therapeutics market further, the region is divided into Japan, Vietnam, Australia & New Zealand, India, Thailand, South Korea, Indonesia, China, and the rest of Asia Pacific that includes Malaysia, Nepal, Singapore, Bangladesh, etc. In the South Korean population, CF is extremely rare, though the disorder is most frequently seen in Caucasians. South Korea’s health expenditure increased by 9.4% in 2018 as compared to 2017, according to the OECD Health Statistics of 2019. These factors are expected to influence the market at a steady rate. In countries like Indonesia, CF is rarely observed as per an article. The problem of under-diagnosis in countries can be due to poverty-related problems because of which CF fails to thrive, and therefore driving the market at a stable growth.
In Vietnam, few incidences of severe hereditary chronic lung disorders are expected in the country. Due to the low incidences of CF, the market is anticipated to grow at a lower rate. In Nepal, there is a prevalence of the metabolic disease as per the NCBI article. There is some government deliberation for the high incidence of congenital disorders, but disorders due to enzymatic deficiencies have not been considered for timely diagnosis and intervention. In Singapore, CF is an uncommon disease. In countries like Malaysia, 16 patients were confirmed to have CF from 1987 to 2003. These factors are estimated to propel the market in the rest of the Asia Pacific region.

COMPETITIVE INSIGHTS
F. Hoffmann-La Roche Ltd, Abbott Laboratories, Allergan PLC, Pfizer Inc, Agilent Technologies, Inc, etc. are some of the prominent companies in the market.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

【レポートの目次】

1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. MARKET DEFINITION
3.2. KEY DRIVERS
3.2.1. ADVANCEMENTS IN THE CYSTIC FIBROSIS THERAPEUTICS TREATMENT
3.2.2. INCREASING INCIDENCE OF CYSTIC FIBROSIS (CF)
3.2.3. RISE IN THE R&D OF NOVEL CYSTIC FIBROSIS THERAPEUTICS
3.3. KEY RESTRAINTS
3.3.1. STRINGENT REGULATION
3.3.2. LOW AWARENESS AMONG DEVELOPING ECONOMIES
4. KEY ANALYTICS
4.1. PORTER’S FIVE FORCE ANALYSIS
4.1.1. THREAT OF NEW ENTRY
4.1.2. THREAT OF SUBSTITUTION
4.1.3. BUYER’S POWER
4.1.4. SUPPLIER’S POWER
4.1.5. COMPETITIVE RIVALRY
4.2. PESTEL ANALYSIS
4.3. OPPORTUNITY MATRIX
4.4. VENDOR LANDSCAPE
4.5. KEY INVESTMENT INSIGHTS
5. MARKET BY ROUTE OF ADMINISTRATION
5.1. INHALE
5.2. ORAL
6. MARKET BY DRUG CLASS
6.1. CFTR MODULATORS
6.2. BRONCHODILATORS
6.3. MUCOLYTIC
6.4. PANCREATIC ENZYME SUPPLEMENTS
7. GEOGRAPHICAL ANALYSIS
7.1. ASIA PACIFIC
7.1.1. CHINA
7.1.2. JAPAN
7.1.3. INDIA
7.1.4. AUSTRALIA & NEW ZEALAND
7.1.5. SOUTH KOREA
7.1.6. THAILAND
7.1.7. INDONESIA
7.1.8. VIETNAM
7.1.9. REST OF ASIA PACIFIC
8. COMPANY PROFILES
8.1. ABBOTT LABORATORIES
8.2. ABBVIE INC
8.3. AGILENT TECHNOLOGIES INC
8.4. ALLERGAN PLC
8.5. F. HOFFMANN-LA ROCHE
8.6. GILEAD SCIENCES INC
8.7. GLAXOSMITHKLINE PLC
8.8. JOHNSON & JOHNSON
8.9. MYLAN N.V
8.10. NOVARTIS AG
8.11. PERKINELMER
8.12. PFIZER INC
8.13. PHARMAXIS LTD
8.14. TEVA PHARMACEUTICAL INDUSTRIES LTD
8.15. VERTEX PHARMACEUTICALS INCORPORATED



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[嚢胞性線維症治療のアジア太平洋市場2020-2058]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆